stockrow
Friday 6 November 2026
Export ICU’s income statement to Excel — free account
SeaStar Medical Holding Corporation
SeaStar Medical Holding Corporation’s revenue for fiscal 2025 (year ended December 2025) was $1.2 million, up 814.1% from fiscal 2024.
- Revenue
- +82.0%
- EPS
- +49.4%
- Free cash flow
- +0.43%
Quarter to June 2026, against a year earlier
1.91
0.01
−0.52%
Follow ICU
Alert me
SeaStar Medical Holding Corporation (ICU) P/E ratio
SeaStar Medical Holding Corporation has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 469× (November 2021) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 4 more quarters | Free account |
Against its own ten years
Low 0.0×
High 469×
Ten-year median
0.0×
Current reading's percentile
95
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BIVI BioVie Inc. compare | n/m |
| LSTA Lisata Therapeutics, Inc. compare | n/m |
| CLRB Cellectar Biosciences, Inc. compare | n/m |
| INTS Intensity Therapeutics Inc. compare | n/m |
| ICU SeaStar Medical Holding Corporation | n/m |
| GDTC CytoMed Therapeutics Limited compare | n/m |
| AZR Azora Therapeutics, Inc. compare | n/m |
| GTBP GT Biopharma, Inc. compare | 0.8× |
| PTN Palatin Technologies, Inc. compare | 13.6× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)